nodes	percent_of_prediction	percent_of_DWPC	metapath
Meloxicam—PGD—Methotrexate—lymphatic system cancer	0.39	0.55	CbGbCtD
Meloxicam—ABCC4—Methotrexate—lymphatic system cancer	0.107	0.152	CbGbCtD
Meloxicam—CYP2C9—Teniposide—lymphatic system cancer	0.0737	0.104	CbGbCtD
Meloxicam—CYP3A4—Cytarabine—lymphatic system cancer	0.0435	0.0615	CbGbCtD
Meloxicam—CYP3A4—Teniposide—lymphatic system cancer	0.0429	0.0606	CbGbCtD
Meloxicam—CYP3A4—Mitoxantrone—lymphatic system cancer	0.03	0.0424	CbGbCtD
Meloxicam—CYP3A4—Vincristine—lymphatic system cancer	0.0206	0.0291	CbGbCtD
Meloxicam—Alopecia—Vincristine—lymphatic system cancer	0.000438	0.0015	CcSEcCtD
Meloxicam—Back pain—Carmustine—lymphatic system cancer	0.000437	0.0015	CcSEcCtD
Meloxicam—Discomfort—Bleomycin—lymphatic system cancer	0.000436	0.00149	CcSEcCtD
Meloxicam—Mental disorder—Vincristine—lymphatic system cancer	0.000434	0.00149	CcSEcCtD
Meloxicam—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000433	0.00148	CcSEcCtD
Meloxicam—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000431	0.00148	CcSEcCtD
Meloxicam—Alopecia—Mitoxantrone—lymphatic system cancer	0.000427	0.00146	CcSEcCtD
Meloxicam—Confusional state—Bleomycin—lymphatic system cancer	0.000426	0.00146	CcSEcCtD
Meloxicam—Vision blurred—Carmustine—lymphatic system cancer	0.000426	0.00146	CcSEcCtD
Meloxicam—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000425	0.00145	CcSEcCtD
Meloxicam—Tremor—Carmustine—lymphatic system cancer	0.000424	0.00145	CcSEcCtD
Meloxicam—Oedema—Bleomycin—lymphatic system cancer	0.000423	0.00145	CcSEcCtD
Meloxicam—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000423	0.00145	CcSEcCtD
Meloxicam—Erythema—Mitoxantrone—lymphatic system cancer	0.00042	0.00144	CcSEcCtD
Meloxicam—Infection—Bleomycin—lymphatic system cancer	0.00042	0.00144	CcSEcCtD
Meloxicam—Anaemia—Carmustine—lymphatic system cancer	0.000418	0.00143	CcSEcCtD
Meloxicam—Back pain—Vincristine—lymphatic system cancer	0.000418	0.00143	CcSEcCtD
Meloxicam—Vomiting—Teniposide—lymphatic system cancer	0.000417	0.00143	CcSEcCtD
Meloxicam—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000414	0.00142	CcSEcCtD
Meloxicam—Asthenia—Fludarabine—lymphatic system cancer	0.000414	0.00142	CcSEcCtD
Meloxicam—Rash—Teniposide—lymphatic system cancer	0.000414	0.00142	CcSEcCtD
Meloxicam—Dermatitis—Teniposide—lymphatic system cancer	0.000413	0.00141	CcSEcCtD
Meloxicam—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000412	0.00141	CcSEcCtD
Meloxicam—Headache—Teniposide—lymphatic system cancer	0.000411	0.00141	CcSEcCtD
Meloxicam—Pruritus—Fludarabine—lymphatic system cancer	0.000408	0.0014	CcSEcCtD
Meloxicam—Back pain—Mitoxantrone—lymphatic system cancer	0.000407	0.00139	CcSEcCtD
Meloxicam—Leukopenia—Carmustine—lymphatic system cancer	0.000405	0.00139	CcSEcCtD
Meloxicam—Anaemia—Vincristine—lymphatic system cancer	0.000399	0.00137	CcSEcCtD
Meloxicam—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000396	0.00136	CcSEcCtD
Meloxicam—Photosensitivity—Methotrexate—lymphatic system cancer	0.000396	0.00136	CcSEcCtD
Meloxicam—Hypotension—Bleomycin—lymphatic system cancer	0.000395	0.00135	CcSEcCtD
Meloxicam—Diarrhoea—Fludarabine—lymphatic system cancer	0.000395	0.00135	CcSEcCtD
Meloxicam—Convulsion—Carmustine—lymphatic system cancer	0.000392	0.00134	CcSEcCtD
Meloxicam—Hypertension—Carmustine—lymphatic system cancer	0.00039	0.00134	CcSEcCtD
Meloxicam—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00039	0.00133	CcSEcCtD
Meloxicam—Nausea—Teniposide—lymphatic system cancer	0.00039	0.00133	CcSEcCtD
Meloxicam—Anaemia—Mitoxantrone—lymphatic system cancer	0.000389	0.00133	CcSEcCtD
Meloxicam—Vertigo—Vincristine—lymphatic system cancer	0.000388	0.00133	CcSEcCtD
Meloxicam—Hepatic failure—Methotrexate—lymphatic system cancer	0.000387	0.00132	CcSEcCtD
Meloxicam—Leukopenia—Vincristine—lymphatic system cancer	0.000386	0.00132	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000385	0.00132	CcSEcCtD
Meloxicam—Myalgia—Carmustine—lymphatic system cancer	0.000385	0.00132	CcSEcCtD
Meloxicam—Anxiety—Carmustine—lymphatic system cancer	0.000384	0.00131	CcSEcCtD
Meloxicam—Paraesthesia—Bleomycin—lymphatic system cancer	0.00038	0.0013	CcSEcCtD
Meloxicam—Malaise—Mitoxantrone—lymphatic system cancer	0.000379	0.0013	CcSEcCtD
Meloxicam—Dyspnoea—Bleomycin—lymphatic system cancer	0.000377	0.00129	CcSEcCtD
Meloxicam—Renal failure acute—Methotrexate—lymphatic system cancer	0.000377	0.00129	CcSEcCtD
Meloxicam—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000376	0.00129	CcSEcCtD
Meloxicam—Convulsion—Vincristine—lymphatic system cancer	0.000374	0.00128	CcSEcCtD
Meloxicam—Hypertension—Vincristine—lymphatic system cancer	0.000373	0.00128	CcSEcCtD
Meloxicam—Confusional state—Carmustine—lymphatic system cancer	0.000372	0.00127	CcSEcCtD
Meloxicam—Oedema—Carmustine—lymphatic system cancer	0.000369	0.00126	CcSEcCtD
Meloxicam—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000369	0.00126	CcSEcCtD
Meloxicam—Decreased appetite—Bleomycin—lymphatic system cancer	0.000368	0.00126	CcSEcCtD
Meloxicam—Myalgia—Vincristine—lymphatic system cancer	0.000368	0.00126	CcSEcCtD
Meloxicam—Visual disturbance—Methotrexate—lymphatic system cancer	0.000367	0.00126	CcSEcCtD
Meloxicam—Cough—Mitoxantrone—lymphatic system cancer	0.000367	0.00126	CcSEcCtD
Meloxicam—Infection—Carmustine—lymphatic system cancer	0.000367	0.00125	CcSEcCtD
Meloxicam—Vomiting—Fludarabine—lymphatic system cancer	0.000367	0.00125	CcSEcCtD
Meloxicam—Convulsion—Mitoxantrone—lymphatic system cancer	0.000364	0.00125	CcSEcCtD
Meloxicam—Rash—Fludarabine—lymphatic system cancer	0.000364	0.00124	CcSEcCtD
Meloxicam—Dermatitis—Fludarabine—lymphatic system cancer	0.000363	0.00124	CcSEcCtD
Meloxicam—Hypertension—Mitoxantrone—lymphatic system cancer	0.000363	0.00124	CcSEcCtD
Meloxicam—Pain—Bleomycin—lymphatic system cancer	0.000362	0.00124	CcSEcCtD
Meloxicam—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000361	0.00124	CcSEcCtD
Meloxicam—Headache—Fludarabine—lymphatic system cancer	0.000361	0.00124	CcSEcCtD
Meloxicam—Tachycardia—Carmustine—lymphatic system cancer	0.00036	0.00123	CcSEcCtD
Meloxicam—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000359	0.00123	CcSEcCtD
Meloxicam—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000358	0.00122	CcSEcCtD
Meloxicam—Myalgia—Mitoxantrone—lymphatic system cancer	0.000358	0.00122	CcSEcCtD
Meloxicam—Anxiety—Mitoxantrone—lymphatic system cancer	0.000357	0.00122	CcSEcCtD
Meloxicam—Discomfort—Mitoxantrone—lymphatic system cancer	0.000354	0.00121	CcSEcCtD
Meloxicam—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000352	0.00121	CcSEcCtD
Meloxicam—Oedema—Vincristine—lymphatic system cancer	0.000352	0.00121	CcSEcCtD
Meloxicam—Infection—Vincristine—lymphatic system cancer	0.00035	0.0012	CcSEcCtD
Meloxicam—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000348	0.00119	CcSEcCtD
Meloxicam—Confusional state—Mitoxantrone—lymphatic system cancer	0.000346	0.00118	CcSEcCtD
Meloxicam—Nervous system disorder—Vincristine—lymphatic system cancer	0.000346	0.00118	CcSEcCtD
Meloxicam—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000345	0.00118	CcSEcCtD
Meloxicam—Hypotension—Carmustine—lymphatic system cancer	0.000345	0.00118	CcSEcCtD
Meloxicam—Oedema—Mitoxantrone—lymphatic system cancer	0.000343	0.00117	CcSEcCtD
Meloxicam—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000343	0.00117	CcSEcCtD
Meloxicam—Nausea—Fludarabine—lymphatic system cancer	0.000343	0.00117	CcSEcCtD
Meloxicam—Infection—Mitoxantrone—lymphatic system cancer	0.000341	0.00117	CcSEcCtD
Meloxicam—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000341	0.00117	CcSEcCtD
Meloxicam—Shock—Mitoxantrone—lymphatic system cancer	0.000338	0.00116	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000336	0.00115	CcSEcCtD
Meloxicam—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000336	0.00115	CcSEcCtD
Meloxicam—Urticaria—Bleomycin—lymphatic system cancer	0.000336	0.00115	CcSEcCtD
Meloxicam—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000335	0.00115	CcSEcCtD
Meloxicam—Body temperature increased—Bleomycin—lymphatic system cancer	0.000334	0.00114	CcSEcCtD
Meloxicam—Insomnia—Carmustine—lymphatic system cancer	0.000334	0.00114	CcSEcCtD
Meloxicam—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000333	0.00114	CcSEcCtD
Meloxicam—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000332	0.00113	CcSEcCtD
Meloxicam—Paraesthesia—Carmustine—lymphatic system cancer	0.000331	0.00113	CcSEcCtD
Meloxicam—Mood swings—Methotrexate—lymphatic system cancer	0.00033	0.00113	CcSEcCtD
Meloxicam—Hypotension—Vincristine—lymphatic system cancer	0.000329	0.00113	CcSEcCtD
Meloxicam—Dyspnoea—Carmustine—lymphatic system cancer	0.000329	0.00113	CcSEcCtD
Meloxicam—Somnolence—Carmustine—lymphatic system cancer	0.000328	0.00112	CcSEcCtD
Meloxicam—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000321	0.0011	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000321	0.0011	CcSEcCtD
Meloxicam—Decreased appetite—Carmustine—lymphatic system cancer	0.000321	0.0011	CcSEcCtD
Meloxicam—Hypotension—Mitoxantrone—lymphatic system cancer	0.000321	0.0011	CcSEcCtD
Meloxicam—Insomnia—Vincristine—lymphatic system cancer	0.000319	0.00109	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000319	0.00109	CcSEcCtD
Meloxicam—Paraesthesia—Vincristine—lymphatic system cancer	0.000316	0.00108	CcSEcCtD
Meloxicam—Constipation—Carmustine—lymphatic system cancer	0.000316	0.00108	CcSEcCtD
Meloxicam—Pain—Carmustine—lymphatic system cancer	0.000316	0.00108	CcSEcCtD
Meloxicam—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000313	0.00107	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000313	0.00107	CcSEcCtD
Meloxicam—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000312	0.00107	CcSEcCtD
Meloxicam—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000308	0.00105	CcSEcCtD
Meloxicam—Decreased appetite—Vincristine—lymphatic system cancer	0.000306	0.00105	CcSEcCtD
Meloxicam—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000306	0.00105	CcSEcCtD
Meloxicam—Somnolence—Mitoxantrone—lymphatic system cancer	0.000305	0.00104	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000304	0.00104	CcSEcCtD
Meloxicam—Feeling abnormal—Carmustine—lymphatic system cancer	0.000304	0.00104	CcSEcCtD
Meloxicam—Fatigue—Vincristine—lymphatic system cancer	0.000304	0.00104	CcSEcCtD
Meloxicam—Asthenia—Bleomycin—lymphatic system cancer	0.000303	0.00104	CcSEcCtD
Meloxicam—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000302	0.00103	CcSEcCtD
Meloxicam—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000302	0.00103	CcSEcCtD
Meloxicam—Pain—Vincristine—lymphatic system cancer	0.000301	0.00103	CcSEcCtD
Meloxicam—Constipation—Vincristine—lymphatic system cancer	0.000301	0.00103	CcSEcCtD
Meloxicam—Asthma—Methotrexate—lymphatic system cancer	0.000301	0.00103	CcSEcCtD
Meloxicam—Pruritus—Bleomycin—lymphatic system cancer	0.000299	0.00102	CcSEcCtD
Meloxicam—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000298	0.00102	CcSEcCtD
Meloxicam—Fatigue—Mitoxantrone—lymphatic system cancer	0.000296	0.00101	CcSEcCtD
Meloxicam—Pancreatitis—Methotrexate—lymphatic system cancer	0.000295	0.00101	CcSEcCtD
Meloxicam—Pain—Mitoxantrone—lymphatic system cancer	0.000293	0.001	CcSEcCtD
Meloxicam—Constipation—Mitoxantrone—lymphatic system cancer	0.000293	0.001	CcSEcCtD
Meloxicam—Abdominal pain—Carmustine—lymphatic system cancer	0.000292	0.000998	CcSEcCtD
Meloxicam—Body temperature increased—Carmustine—lymphatic system cancer	0.000292	0.000998	CcSEcCtD
Meloxicam—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000288	0.000986	CcSEcCtD
Meloxicam—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000288	0.000986	CcSEcCtD
Meloxicam—Pancytopenia—Methotrexate—lymphatic system cancer	0.000286	0.000977	CcSEcCtD
Meloxicam—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000283	0.000967	CcSEcCtD
Meloxicam—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000281	0.00096	CcSEcCtD
Meloxicam—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000279	0.000956	CcSEcCtD
Meloxicam—Body temperature increased—Vincristine—lymphatic system cancer	0.000279	0.000953	CcSEcCtD
Meloxicam—Abdominal pain—Vincristine—lymphatic system cancer	0.000279	0.000953	CcSEcCtD
Meloxicam—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000274	0.000939	CcSEcCtD
Meloxicam—Urticaria—Mitoxantrone—lymphatic system cancer	0.000273	0.000933	CcSEcCtD
Meloxicam—Hypersensitivity—Carmustine—lymphatic system cancer	0.000272	0.00093	CcSEcCtD
Meloxicam—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000271	0.000928	CcSEcCtD
Meloxicam—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000271	0.000928	CcSEcCtD
Meloxicam—Vomiting—Bleomycin—lymphatic system cancer	0.000269	0.00092	CcSEcCtD
Meloxicam—Infestation NOS—Methotrexate—lymphatic system cancer	0.000268	0.000917	CcSEcCtD
Meloxicam—Drowsiness—Methotrexate—lymphatic system cancer	0.000268	0.000917	CcSEcCtD
Meloxicam—Infestation—Methotrexate—lymphatic system cancer	0.000268	0.000917	CcSEcCtD
Meloxicam—Rash—Bleomycin—lymphatic system cancer	0.000267	0.000912	CcSEcCtD
Meloxicam—Dermatitis—Bleomycin—lymphatic system cancer	0.000266	0.000911	CcSEcCtD
Meloxicam—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000266	0.000909	CcSEcCtD
Meloxicam—Asthenia—Carmustine—lymphatic system cancer	0.000265	0.000906	CcSEcCtD
Meloxicam—Renal failure—Methotrexate—lymphatic system cancer	0.000264	0.000902	CcSEcCtD
Meloxicam—Stomatitis—Methotrexate—lymphatic system cancer	0.000261	0.000894	CcSEcCtD
Meloxicam—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000261	0.000891	CcSEcCtD
Meloxicam—Hypersensitivity—Vincristine—lymphatic system cancer	0.00026	0.000888	CcSEcCtD
Meloxicam—Sweating—Methotrexate—lymphatic system cancer	0.000257	0.000879	CcSEcCtD
Meloxicam—Haematuria—Methotrexate—lymphatic system cancer	0.000256	0.000874	CcSEcCtD
Meloxicam—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000254	0.000867	CcSEcCtD
Meloxicam—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000253	0.000865	CcSEcCtD
Meloxicam—Asthenia—Vincristine—lymphatic system cancer	0.000253	0.000865	CcSEcCtD
Meloxicam—Diarrhoea—Carmustine—lymphatic system cancer	0.000253	0.000864	CcSEcCtD
Meloxicam—Nausea—Bleomycin—lymphatic system cancer	0.000251	0.000859	CcSEcCtD
Meloxicam—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00025	0.000856	CcSEcCtD
Meloxicam—Asthenia—Mitoxantrone—lymphatic system cancer	0.000246	0.000842	CcSEcCtD
Meloxicam—Dizziness—Carmustine—lymphatic system cancer	0.000244	0.000835	CcSEcCtD
Meloxicam—Haemoglobin—Methotrexate—lymphatic system cancer	0.000242	0.000827	CcSEcCtD
Meloxicam—Diarrhoea—Vincristine—lymphatic system cancer	0.000241	0.000825	CcSEcCtD
Meloxicam—Haemorrhage—Methotrexate—lymphatic system cancer	0.000241	0.000823	CcSEcCtD
Meloxicam—Hepatitis—Methotrexate—lymphatic system cancer	0.000241	0.000823	CcSEcCtD
Meloxicam—Pharyngitis—Methotrexate—lymphatic system cancer	0.000239	0.000817	CcSEcCtD
Meloxicam—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000238	0.000813	CcSEcCtD
Meloxicam—Urethral disorder—Methotrexate—lymphatic system cancer	0.000236	0.000807	CcSEcCtD
Meloxicam—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000235	0.000803	CcSEcCtD
Meloxicam—Vomiting—Carmustine—lymphatic system cancer	0.000235	0.000803	CcSEcCtD
Meloxicam—Dizziness—Vincristine—lymphatic system cancer	0.000233	0.000797	CcSEcCtD
Meloxicam—Rash—Carmustine—lymphatic system cancer	0.000233	0.000796	CcSEcCtD
Meloxicam—Dermatitis—Carmustine—lymphatic system cancer	0.000233	0.000795	CcSEcCtD
Meloxicam—Visual impairment—Methotrexate—lymphatic system cancer	0.000232	0.000793	CcSEcCtD
Meloxicam—Headache—Carmustine—lymphatic system cancer	0.000231	0.000791	CcSEcCtD
Meloxicam—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000228	0.000778	CcSEcCtD
Meloxicam—Eye disorder—Methotrexate—lymphatic system cancer	0.000225	0.000769	CcSEcCtD
Meloxicam—Tinnitus—Methotrexate—lymphatic system cancer	0.000224	0.000768	CcSEcCtD
Meloxicam—Vomiting—Vincristine—lymphatic system cancer	0.000224	0.000766	CcSEcCtD
Meloxicam—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000223	0.000764	CcSEcCtD
Meloxicam—Rash—Vincristine—lymphatic system cancer	0.000222	0.00076	CcSEcCtD
Meloxicam—Dermatitis—Vincristine—lymphatic system cancer	0.000222	0.000759	CcSEcCtD
Meloxicam—Headache—Vincristine—lymphatic system cancer	0.000221	0.000755	CcSEcCtD
Meloxicam—Nausea—Carmustine—lymphatic system cancer	0.000219	0.00075	CcSEcCtD
Meloxicam—Angiopathy—Methotrexate—lymphatic system cancer	0.000218	0.000747	CcSEcCtD
Meloxicam—Vomiting—Mitoxantrone—lymphatic system cancer	0.000218	0.000746	CcSEcCtD
Meloxicam—Immune system disorder—Methotrexate—lymphatic system cancer	0.000217	0.000744	CcSEcCtD
Meloxicam—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000217	0.000742	CcSEcCtD
Meloxicam—Rash—Mitoxantrone—lymphatic system cancer	0.000216	0.00074	CcSEcCtD
Meloxicam—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000216	0.00074	CcSEcCtD
Meloxicam—Headache—Mitoxantrone—lymphatic system cancer	0.000215	0.000735	CcSEcCtD
Meloxicam—Alopecia—Methotrexate—lymphatic system cancer	0.000213	0.000728	CcSEcCtD
Meloxicam—Mental disorder—Methotrexate—lymphatic system cancer	0.000211	0.000721	CcSEcCtD
Meloxicam—Malnutrition—Methotrexate—lymphatic system cancer	0.000209	0.000717	CcSEcCtD
Meloxicam—Erythema—Methotrexate—lymphatic system cancer	0.000209	0.000717	CcSEcCtD
Meloxicam—Nausea—Vincristine—lymphatic system cancer	0.000209	0.000716	CcSEcCtD
Meloxicam—Dysgeusia—Methotrexate—lymphatic system cancer	0.000205	0.000702	CcSEcCtD
Meloxicam—Nausea—Mitoxantrone—lymphatic system cancer	0.000204	0.000697	CcSEcCtD
Meloxicam—Back pain—Methotrexate—lymphatic system cancer	0.000203	0.000693	CcSEcCtD
Meloxicam—Vision blurred—Methotrexate—lymphatic system cancer	0.000197	0.000675	CcSEcCtD
Meloxicam—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000194	0.000665	CcSEcCtD
Meloxicam—Anaemia—Methotrexate—lymphatic system cancer	0.000194	0.000662	CcSEcCtD
Meloxicam—Malaise—Methotrexate—lymphatic system cancer	0.000189	0.000646	CcSEcCtD
Meloxicam—Vertigo—Methotrexate—lymphatic system cancer	0.000188	0.000644	CcSEcCtD
Meloxicam—Leukopenia—Methotrexate—lymphatic system cancer	0.000188	0.000642	CcSEcCtD
Meloxicam—Cough—Methotrexate—lymphatic system cancer	0.000183	0.000625	CcSEcCtD
Meloxicam—Convulsion—Methotrexate—lymphatic system cancer	0.000181	0.000621	CcSEcCtD
Meloxicam—Myalgia—Methotrexate—lymphatic system cancer	0.000178	0.00061	CcSEcCtD
Meloxicam—Arthralgia—Methotrexate—lymphatic system cancer	0.000178	0.00061	CcSEcCtD
Meloxicam—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000177	0.000606	CcSEcCtD
Meloxicam—Discomfort—Methotrexate—lymphatic system cancer	0.000176	0.000603	CcSEcCtD
Meloxicam—Confusional state—Methotrexate—lymphatic system cancer	0.000172	0.00059	CcSEcCtD
Meloxicam—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000171	0.000585	CcSEcCtD
Meloxicam—Infection—Methotrexate—lymphatic system cancer	0.00017	0.000581	CcSEcCtD
Meloxicam—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000168	0.000574	CcSEcCtD
Meloxicam—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000167	0.000573	CcSEcCtD
Meloxicam—Skin disorder—Methotrexate—lymphatic system cancer	0.000166	0.000568	CcSEcCtD
Meloxicam—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000165	0.000565	CcSEcCtD
Meloxicam—Hypotension—Methotrexate—lymphatic system cancer	0.00016	0.000547	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000156	0.000533	CcSEcCtD
Meloxicam—Insomnia—Methotrexate—lymphatic system cancer	0.000155	0.000529	CcSEcCtD
Meloxicam—Paraesthesia—Methotrexate—lymphatic system cancer	0.000154	0.000525	CcSEcCtD
Meloxicam—Dyspnoea—Methotrexate—lymphatic system cancer	0.000152	0.000521	CcSEcCtD
Meloxicam—Somnolence—Methotrexate—lymphatic system cancer	0.000152	0.00052	CcSEcCtD
Meloxicam—Dyspepsia—Methotrexate—lymphatic system cancer	0.00015	0.000515	CcSEcCtD
Meloxicam—Decreased appetite—Methotrexate—lymphatic system cancer	0.000149	0.000508	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000148	0.000505	CcSEcCtD
Meloxicam—Fatigue—Methotrexate—lymphatic system cancer	0.000147	0.000504	CcSEcCtD
Meloxicam—Pain—Methotrexate—lymphatic system cancer	0.000146	0.0005	CcSEcCtD
Meloxicam—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000141	0.000482	CcSEcCtD
Meloxicam—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00014	0.000478	CcSEcCtD
Meloxicam—Urticaria—Methotrexate—lymphatic system cancer	0.000136	0.000465	CcSEcCtD
Meloxicam—Abdominal pain—Methotrexate—lymphatic system cancer	0.000135	0.000462	CcSEcCtD
Meloxicam—Body temperature increased—Methotrexate—lymphatic system cancer	0.000135	0.000462	CcSEcCtD
Meloxicam—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000126	0.000431	CcSEcCtD
Meloxicam—Asthenia—Methotrexate—lymphatic system cancer	0.000123	0.00042	CcSEcCtD
Meloxicam—Pruritus—Methotrexate—lymphatic system cancer	0.000121	0.000414	CcSEcCtD
Meloxicam—Diarrhoea—Methotrexate—lymphatic system cancer	0.000117	0.0004	CcSEcCtD
Meloxicam—Dizziness—Methotrexate—lymphatic system cancer	0.000113	0.000387	CcSEcCtD
Meloxicam—Vomiting—Methotrexate—lymphatic system cancer	0.000109	0.000372	CcSEcCtD
Meloxicam—Rash—Methotrexate—lymphatic system cancer	0.000108	0.000369	CcSEcCtD
Meloxicam—Dermatitis—Methotrexate—lymphatic system cancer	0.000108	0.000368	CcSEcCtD
Meloxicam—Headache—Methotrexate—lymphatic system cancer	0.000107	0.000366	CcSEcCtD
Meloxicam—Nausea—Methotrexate—lymphatic system cancer	0.000102	0.000347	CcSEcCtD
